Oculogyric Crisis - An Acute Dystonia with Olanzapine

2015 ◽  
Vol 18 (3) ◽  
Author(s):  
Varun S Mehta
Author(s):  
Cansu MERCAN IŞIK ◽  
Belde DEMİRCİ ◽  
Seda Aybüke SARI ◽  
Ayla UZUN ÇİÇEK

2021 ◽  
pp. 201010582110408 ◽  
Author(s):  
Howard Cai Hao Khoe ◽  
Vivian Shi Yin Wong

This report documents a rare case of delayed-onset multiple acute dystonias after treatment with low dose intramuscular (IM) haloperidol lactate injection in a setting of non-neuroleptic drug overdose. The drug–drug interactions between haloperidol and high levels of paracetamol and naproxen are deliberated upon. A 25-year-old Asian female was admitted after an intentional overdose of medications (paracetamol, naproxen and pregabalin). She received 5 mg of IM haloperidol injection for agitation. 21 hours later she experienced mild intermittent ocular deviation in an upward and outward direction and generalised stiffness, which were self-resolving. An hour later, she required another 2.5 mg of IM haloperidol injection for further agitation. In the 35 hours following her first IM haloperidol (13 hours after the second IM haloperidol), she developed a total of three episodes of oculogyric crisis (OGC) with torticollis. Each episode was treated promptly with IM diphenhydramine 25 mg, and there was remission of symptoms within 15 minutes of treatment. An objective causality assessment revealed a definite relationship between the episodes of acute dystonia with IM haloperidol therapy. Where oral alternatives and IM atypical antipsychotics/benzodiazepines are unavailable, rapid tranquillisation with a high-potency typical antipsychotic is a possibility. However, consideration should be made to combine haloperidol with an anticholinergic agent as prophylaxis against acute dystonia, especially in the setting of drug overdose, even if it is that of a non-neuroleptic drug (in this case, paracetamol and naproxen).


1996 ◽  
Vol 11 (6) ◽  
pp. 756-758 ◽  
Author(s):  
Jong S. Kim ◽  
Hyo K. Kim ◽  
Joo H. Im ◽  
Myoung C. Lee

2016 ◽  
Vol 22 ◽  
pp. e78-e79
Author(s):  
Lars Wictor ◽  
Klas Wictorin ◽  
Håkan Widner ◽  
Andreas Puschmann

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Semih Erden ◽  
Hurşit Ferahkaya
Keyword(s):  
Low Dose ◽  

2002 ◽  
Vol 36 (5) ◽  
pp. 827-830 ◽  
Author(s):  
Deborah V Kelly ◽  
Lizanne C Béïque ◽  
M Ian Bowmer

OBJECTIVE: To report a case of suspected extrapyramidal symptoms (EPS) in a patient initiated on ritonavir and indinavir while taking risperidone for a tic disorder. CASE SUMMARY: A 35-year-old white man with AIDS received risperidone 2 mg twice daily for treatment of a Tourette's-like tic disorder. Ritonavir and indinavir were initiated, and 1 week later, he experienced significantly impaired swallowing, speaking, and breathing, and worsening of his existing tremors. Ritonavir and indinavir were discontinued. On the same day, the patient increased the risperidone dosage to 3 mg twice daily. Symptoms continued to worsen over the next 3 days. All investigations and laboratory parameters were unremarkable, and vital signs were stable. Risperidone was discontinued and clonazepam initiated. Three days later, the patient's symptoms were significantly improved. DISCUSSION: The symptoms described herein are consistent with neuroleptic-induced acute dystonia and potentially neuroleptic-induced parkinsonism. We believe this adverse effect occurred as a result of a drug interaction between ritonavir/indinavir and risperidone. Based on the pharmacokinetics of these medications, we hypothesize that inhibition of CYP2D6 and CYP3A4 by ritonavir and indinavir may have resulted in an accumulation of the active moiety of risperidone, which may explain the occurrence of EPS in this patient. CONCLUSIONS: This is the second published case report describing a suspected drug interaction with ritonavir, indinavir, and risperidone. Caution is warranted when risperidone is prescribed with ritonavir/indinavir, and possibly with other antiretrovirals that inhibit the same pathways.


2018 ◽  
Vol 31 (4) ◽  
pp. 396-399 ◽  
Author(s):  
Sema Baykara ◽  
Muhammed Fatih Tabara ◽  
Sevda Korkmaz ◽  
Murad Atmaca
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document